Cogent Biosciences Stock Performance
| COGT Stock | USD 9.62 0.32 3.44% |
The firm shows a Beta (market volatility) of -0.44, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Cogent Biosciences are expected to decrease at a much lower rate. During the bear market, Cogent Biosciences is likely to outperform the market. At this point, Cogent Biosciences has a negative expected return of -0.27%. Please make sure to confirm Cogent Biosciences' total risk alpha, as well as the relationship between the kurtosis and day typical price , to decide if Cogent Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Cogent Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain comparatively stable which may send shares a bit higher in March 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return 3.44 | Five Day Return 8.95 | Year To Date Return 23.33 | Ten Year Return (7.50) | All Time Return (7.50) |
Last Split Factor 1:4 | Dividend Date 2020-11-09 | Last Split Date 2020-11-09 |
1 | Acquisition by Ros Matthew of 60000 shares of Cogent Biosciences at 8.45 subject to Rule 16b-3 | 11/11/2024 |
2 | Piper Sandler stays bullish on Cogent shares, cites clinical profile strength for bezu | 11/25/2024 |
3 | Acquisition by Ferrante Karen Jean of 2513 shares of Cogent Biosciences at 8.02 subject to Rule 16b-3 | 11/26/2024 |
4 | Why Is Cogent Biosciences, Inc. Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds - Insider Monkey | 12/04/2024 |
5 | Why Is Cogent Biosciences Stock Trading Higher On Monday | 12/09/2024 |
6 | What is HC Wainwrights Estimate for COGT FY2024 Earnings | 12/13/2024 |
7 | Cogent Biosciences, Inc. Given Average Recommendation of Moderate Buy by Analysts - MarketBeat | 12/20/2024 |
8 | Acquisition by Ferrante Karen Jean of 2785 shares of Cogent Biosciences at 7.8 subject to Rule 16b-3 | 12/31/2024 |
9 | Cogent Biosciences Announces Presentation at the 43rd AnnualJ.P. Morgan Healthcare Conference | 01/08/2025 |
10 | Cogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics | 01/13/2025 |
11 | Acquisition by Pinnow Cole of 43750 shares of Cogent Biosciences at 7.598 subject to Rule 16b-3 | 01/14/2025 |
12 | This Cogent Biosciences Insider Increased Their Holding By 2,085 percent Last Year | 01/17/2025 |
13 | Acquisition by Kearns Evan of 230000 shares of Cogent Biosciences at 8.89 subject to Rule 16b-3 | 01/23/2025 |
14 | Inside Cogents Next Big Move Key Presentation Set for Guggenheim Conference - StockTitan | 01/30/2025 |
| Begin Period Cash Flow | 141.1 M |
Cogent |
Cogent Biosciences Relative Risk vs. Return Landscape
If you would invest 1,187 in Cogent Biosciences on November 2, 2024 and sell it today you would lose (225.00) from holding Cogent Biosciences or give up 18.96% of portfolio value over 90 days. Cogent Biosciences is currently does not generate positive expected returns and assumes 4.2044% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Cogent, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cogent Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cogent Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cogent Biosciences, and traders can use it to determine the average amount a Cogent Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0634
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | COGT |
Estimated Market Risk
| 4.2 actual daily | 37 63% of assets are more volatile |
Expected Return
| -0.27 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cogent Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cogent Biosciences by adding Cogent Biosciences to a well-diversified portfolio.
Cogent Biosciences Fundamentals Growth
Cogent Stock prices reflect investors' perceptions of the future prospects and financial health of Cogent Biosciences, and Cogent Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cogent Stock performance.
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.44 | ||||
| Current Valuation | 855.55 M | ||||
| Shares Outstanding | 110.46 M | ||||
| Price To Earning | (5.03) X | ||||
| Price To Book | 5.21 X | ||||
| Price To Sales | 1,321 X | ||||
| Gross Profit | (121.63 M) | ||||
| EBITDA | (205.86 M) | ||||
| Net Income | (192.41 M) | ||||
| Cash And Equivalents | 325.56 M | ||||
| Cash Per Share | 4.95 X | ||||
| Total Debt | 18.85 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 11.96 X | ||||
| Book Value Per Share | 1.85 X | ||||
| Cash Flow From Operations | (153.62 M) | ||||
| Earnings Per Share | (2.48) X | ||||
| Market Capitalization | 1.06 B | ||||
| Total Asset | 313.44 M | ||||
| Retained Earnings | (603.62 M) | ||||
| Working Capital | 232.6 M | ||||
| Current Asset | 37.62 M | ||||
| Current Liabilities | 21.06 M | ||||
About Cogent Biosciences Performance
Assessing Cogent Biosciences' fundamental ratios provides investors with valuable insights into Cogent Biosciences' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Cogent Biosciences is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.71) | (0.74) | |
| Return On Capital Employed | (0.87) | (0.91) | |
| Return On Assets | (0.71) | (0.74) | |
| Return On Equity | (0.86) | (0.90) |
Things to note about Cogent Biosciences performance evaluation
Checking the ongoing alerts about Cogent Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cogent Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cogent Biosciences generated a negative expected return over the last 90 days | |
| Cogent Biosciences has high historical volatility and very poor performance | |
| Net Loss for the year was (192.41 M) with loss before overhead, payroll, taxes, and interest of (121.63 M). | |
| Cogent Biosciences currently holds about 325.56 M in cash with (153.62 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95. | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Inside Cogents Next Big Move Key Presentation Set for Guggenheim Conference - StockTitan |
- Analyzing Cogent Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cogent Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Cogent Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cogent Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cogent Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cogent Biosciences' stock. These opinions can provide insight into Cogent Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.